SCHEMBL7527196

SCHEMBL7527196

COc1ccc(-c2ccc(C)cc2)cc1P(=O)(OC)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ HPGD P15428 3/20 0.43
▸ PDGFRB P09619 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ ACHE P22303 1/20 0.41
▸ CYP3A4 P08684 2/20 0.38
▸ ALKBH3 Q96Q83 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ CTNNB1 P35222 1/20 0.36
▸ WNT3A P56704 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CTSA P10619 1/20 0.36
▸ ALOX5 P09917 2/20 0.35
▸ TNKS O95271 1/20 0.35
▸ TNKS2 Q9H2K2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10722080 0.86 ACHE (0.52) ALDH1A1HPGDACHECYP3A4LMNA
SCHEMBL7188818 0.83 CFD (0.45) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL7188341 0.82 PTPN11 (0.40) ALDH1A1CYP3A4LMNAPKMMEN1
SCHEMBL7527444 0.81 HPGD (0.39) ALDH1A1HPGDCYP3A4LMNAPKM
SCHEMBL7195829 0.81 MGAM (0.37) ALDH1A1HPGDPDGFRBPDGFRAALKBH3
SCHEMBL7183095 0.80 MCL1 (0.47) ALDH1A1HPGDMEN1KMT2AKDM4E
SCHEMBL7183230 0.79 PTPN5 (0.36) ALDH1A1HPGDALKBH3LMNA
SCHEMBL7182874 0.79 GAK (0.38) ALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL7190202 0.78 TRPA1 (0.40) ALDH1A1HPGDCYP3A4KDM4EALOX5
SCHEMBL7597964 0.77 NPC1 (0.33) ALDH1A1HPGDLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 — — US disclosed
EP-1244677-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-10-02 — — EP disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 — — US disclosed
WO-2001046203-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA ALDH1A1 600/4885HPGD 2990/4885PDGFRB 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback